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The economic and clinical burden of ventilator-associated pneumonia (VAP) is uncontested. In many hospitals, VAP sur-
veillance is conducted to identify outbreaks and to monitor infection rates. Here, we discuss the concept of benchmarking
in health care as modeled on industry, and we contribute personal arguments against considering the VAP rate as a potential
candidate for benchmarking or for monitoring the quality of patient care. Accurate benchmarking of VAP rates currently
seems to be unfeasible, because the patient case mix is often too diverse and complicated to be adjusted for, and diagnostic
criteria and surveillance protocols vary. Thus, the risk of drawing inaccurate comparisons is high. In contrast, some risk
factors for VAP are modifiable and can be monitored and used as quality indicators. Process-oriented surveillance permits
bypass of case-mix and diagnostic constraints. A well-defined interhospital surveillance system is necessary to prove that
interventions on procedures do really lead to a reduction of VAP rates.
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Nosocomial infections are common com-
plications of a hospital stay [1]. Of these,
ventilator-associated pneumonia (VAP)
represents 5%–18% of all infections [2, 3].
In a study involving 198 intensive care
units (ICUs), the lung was the most com-
mon site of infection (68%) among pa-
tients with sepsis [4]. Overall, reported
mortality rates for VAP have a range of
24%–50% and can reach 76% in specific
settings [5]. Although there are pub-
lications reporting no attributable mor-
tality to VAP [5, 6], most authors believe
that it contributes to 7%–30% of addi-
tional mortality [7–9]. An additional 4–
32 ventilator-days are ascribed to VAP [9,
10], and estimated attributable costs for 1
episode of VAP are reported to be as high
as US $10,000 [11], US $16,000 [9], or
even more [12].
At least 30% of all nosocomial infec-
tions are believed to be preventable [13].
Lowering the incidence of VAP would be
an important quality improvement for pa-
tient safety. In a society where consumers
consult restaurant ratings before making
dinner reservations, the drive for “hospital
ratings” is already palpable, and hospital
leaders are more interested than ever in
improving quality of care and in lowering
costs [14]. In the United States, the Joint
Commission [15] ratings propose specific
patient safety targets before awarding ac-
creditation, and this culture is already
traveling overseas, with the establishment
of the Joint Commission International
Hospital Accreditation Process.
But can VAP rates be used to draw con-
clusions? Moreover, is it fair to compare
pneumonia rates across institutions? Is
benchmarking meaningful, valuable, and,
finally, to be recommended?
BENCHMARKING:
COPYING THE BEST
Benchmarking was defined in 1989 by
Camp as “a continuous process of mea-
suring products, services and practices
against the toughest competitors or those
companies recognized as industry leaders”
[16, p. 320]. In the early 1980s, the Xerox
company found itself increasingly vulner-
able to intensive competition from both
US and Japanese companies, and its mar-
ket share in copiers came down sharply
from 86% in 1974 to only 17% in 1984.
A “leadership through quality” policy was
instigated with the revolutionary concept
of “benchmarking.” Xerox looked first at
internal company processes, followed by
an assessment of its competitors, and col-
lected data on key processes of best-prac-
tice companies. These critical processes
were then analyzed to identify and define
improvement [17]. To date, Xerox has
conducted 1400 benchmarking studies
and benchmarks itself against the best
firms in every aspect of the market. The
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company now attributes 10% of annual
productivity improvements to the lessons
of benchmarking, and Xerox products are
themselves once again industry bench-
marks in certain product groups.
Benchmarking has gained widespread
acceptance in the private industry and is
thought to lead to breakthrough improve-
ments [18]. It serves to compare results,
as well as structures and processes leading
to these results. Two main types of bench-
marking in private industry have evolved
over time. First, internal benchmarking
compares variations in differing units or
departments within the same institution.
Similar internal functions serve as pilot
sites for conducting benchmarking
through analysis of all processes involved
in the task. A more covert internal bench-
marking exists, which is the comparison
of all the processes and policies of the same
unit at different times. Second, competi-
tive benchmarking is the study and mea-
surement of one’s policies against those of
the best competitors.
BENCHMARKING IN HEALTH
CARE: BUSINESS AT THE
BEDSIDE
In health care settings, many attempts to
benchmark have also been made on the
basis of “best practices” [19], especially,
but not exclusively, in the area of cardio-
vascular medicine [20]. Theoretically, ev-
ery interhospital comparison adjusted for
patient case mix can be considered to be
benchmarking. Examples include the call-
to-needle time for thrombolysis in acute
myocardial infarction [21], compliance
with guidelines in the management of
chronic heart failure [22], b-blocker pre-
scription after myocardial infarction [23],
treatment modalities for peripheral arte-
rial disease [24], care for schizophrenia in
the health care system [25], and the han-
dling of recommendations for adolescent
sexual health on the basis of comparisons
with international best practices [26].
These were examples related to the process
level of benchmarking. Examples of out-
come benchmarking would be the assess-
ment of the mortality of patients with di-
abetes; questioning the quality of diabetes
care [27]; assessment of mortality of my-
ocardial infarction related to b-blocker use
[28]; assessment of survival after coronary
artery bypass grafting, according to hos-
pital-procedure volume [29]; and man-
agement of postoperative pain [30].
In the case of VAP, possible scopes of
benchmarking could be the reduction of
VAP risk by analysis and comparison of
risk factors, prevention by comparison of
preventive measures, comparison of clin-
ical and/or microbiological trends, com-
parison of true incidence rates, and treat-
ment and choice of antibiotics, with their
impact on outcome. Other potential ad-
vantages would be the development of im-
proved surveillance systems to follow
emerging trends, catalyze action, activate
administrative support, motivate health
care staff, and acquire positive public and
media attention in the overall context of
the current trend for hospital ratings and
public reporting. But is this really possible,
and what are the difficulties to be en-
countered along the way?
VAP AS A CANDIDATE FOR
BENCHMARKING
Case definitions. The key to bench-
marking has to be a defined, unequivocal
diagnosis. Although there are reports
combining microbiological and clinical in-
formation to adjudicate VAP as being pos-
sible or probable [5], currently, there is no
“gold standard” diagnosis. Histological
proof, the best means of definitively di-
agnosing pulmonary infection, is rarely
obtained and is often prohibited by disease
severity. Bronchoscopic examination is
not always possible. It is agreed that the
definition of VAP is one of the most dif-
ficult diagnostic challenges in the critically
ill patient [5, 31]. Established clinical cri-
teria alone, such as the presence of new
or progressive airspace disease on chest
radiography, together with fever, leuko-
cytosis, and purulent tracheobronchial se-
cretions, have been shown to be of limited
diagnostic value [32, 33]. Even postmor-
tem studies, which correlate histological
diagnoses with the bacterial burden, have
not identified a definitive quantitative
threshold [34]. Despite these deficiencies
in defining VAP, many expert societies
have published recommendations for di-
agnosis, which themselves are heteroge-
neous [35–38].
Disease severity. Even if case defini-
tions of VAP can be clarified for the pur-
poses of surveillance, the assessment of
disease severity that is necessary for quan-
tification—and, ultimately, for compari-
son—is more difficult. For example, in
contrast to the well-established APACHE
II score that predicts patient mortality in
the ICU [39], there is currently no stan-
dardized, well-accepted scale for assessing
disease severity of pneumonia [40], al-
though attempts have been made to im-
plement such scoring systems [41–43].
Surveillance. A sophisticated surveil-
lance system is not absolutely necessary to
see improvements of VAP rates in a single
setting. Time-ordered analysis can be
more easily performed to gauge improve-
ment in the same hospital. Difficulties
arise when benchmarking is attempted,
and surveillance is integral to benchmark-
ing. For this purpose, accurate surveillance
is complex and requires the collation and
assessment of data in varied formats: med-
ication chart, medical record, laboratory
data (including the microbiological re-
ports), institutional pharmacy, and ad-
ministrative databases, even including in-
terviews with medical staff. This requires
dedicated, specialized staff and is often
time-consuming. Some conditions require
surveillance to be continued after patient
discharge. It is not surprising, therefore,
that surveillance protocols and definitions
differ from one center to another. Im-
proving the quality of comparable data
certainly requires an agency or a private
association that plans, coordinates, and
propagates harmonization of surveillance
systems, such as the Centers for Disease
Control and Prevention, the National
Quality Forum [44], or the Institute for
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Healthcare Improvement in the United
States [45].
Surveillance of VAP itself would prob-
ably not reduce infection rates in the ab-
sence of intervention. It would require at
least the feedback of the results observed,
which is already an intervention [46–49].
Although their results were not based on
randomized trials, German authors have
shown that VAP rates decreased in hos-
pitals participating in their national sur-
veillance system [47, 48]. The availability
of a microbiological surveillance system is
classified as category of evidence grades
IA–IB in guidelines for the prevention of
nosocomial pneumonia [36]. Certainly,
national or international surveillance pro-
grams exist, with a potential of standard-
izing main outcome parameters [50].
However, the degree of detail of the data
collected is vital. Surveillance including
only core data or VAP rates will not be
able to take into account the case mix of
the individual patient populations.
Case mix. Case mix is the “curve ball”
of any outcome benchmarking like VAP
rates, and its impact on results should not
be underestimated [51], which is true for
most disease conditions among critically
ill patients. These patients are difficult to
categorize into comparable groups. They
differ across age, immunosuppression
status, comorbidities, smoking and im-
munization history, recent hospitalization,
and even dental hygiene. The admission
conditions that dictate the necessity for
invasive procedures also represent risk fac-
tors for nosocomial infections and thus act
as propensity factors. Even more con-
founding, patients are dynamic hosts
themselves; their conditions vary over
time during hospital stay and change in
terms of risk factors. Among patients with
VAP, disease severity and attributable mor-
tality will be overestimated if only ICU
admission criteria are retrospectively as-
cribed to each episode of VAP. Case mix
is difficult and rarely accounted for in a
meticulous way, thus frequently inviting
inaccurate comparisons [52]. Underad-
justment will punish the excellent centers.
Statistics. Besides the problem of case
mix, relating VAP rates to risk factors to
allow significant comparisons requires so-
phisticated adjustment for numerous pa-
rameters. The sample size needs to be
massive for meaningful data to be col-
lected. VAP incidence described as epi-
sodes per 1000 patient-days may under-
estimate the incidence expressed as
episodes per 1000 ventilator-days by al-
most 40%, thus demonstrating that the
method of reporting VAP rates has a sig-
nificant impact on risk estimates [7]. Ac-
cordingly, clinicians in charge of patient-
care policies should be aware of how to
read and compare VAP rates [53]. Pro-
vided that the sample size is sufficient,
problems related to statistics would be
simple to overcome by consensus. This
latter option might be to decide on ven-
tilator-days at risk during a defined, mean-
ingful study period as the main denomi-
nator of incidence density [7] and to assess
only the first episode of VAP, to minimize
clustering effects. Prevalence studies can-
not be used to collect this type of infor-
mation. Surveillance based on an inci-
dence survey is more resource consuming
than are prevalence surveys. The assess-
ment of ventilator-days at risk demands
ongoing continuous surveillance and in-
dividual patient data collection and mon-
itoring [7], which are still rarely available
in most ICUs.
To benchmark or not to benchmark
VAP rates? In summary, accurate
benchmarking for VAP rates seems to be
currently unfeasible, even among wards of
the same hospital. Limitations are mainly
due to difficulties in adjustment for case
mix and differences in the surveillance
structure and techniques.
The use of selected and simple, al-
though not completely sensitive or spe-
cific, case definitions (segmentation) is
theoretically tempting for ICUs that have
achieved very low VAP rates but would
signify a selection bias toward institutions
to be compared. We believe that this ap-
proach should be considered only when
VAP rates are approaching zero in selected
patient populations. However, this is not
the ultimate goal of nationwide or regional
benchmarking. Moreover, for VAP, there
is a lack of a sequence of adequately pow-
ered clinical trials to determine the “stan-
dards” for benchmark, such as for the
treatment of acute myocardial infarction
[21, 22] and severe chronic heart failure
[22]. This is another argument against the
use of VAP as a benchmark.
Benchmarking demands attention, es-
pecially if the results have to be reported
in public. It is easy to compare results in-
correctly and inaccurately [54]. Although
there is some evidence of a positive cor-
relation between accreditation scores and
public disclosure—suggesting that the
public disclosure of accreditation reports
should be encouraged [55]—erroneous
comparisons focus public and patient at-
tention even in the absence of real clinical
problems. Such data are vulnerable to pro-
found misuse by the media, health insur-
ance companies, and even boards of con-
trol and may lead to invalid judgment
and uncontrolled, erroneous information.
Moreover, unjustified condemnation can
lead to staff demotivation and thus back-
fire in respect to the goal of quality im-
provement. This opinion is equally shared
by others who identified the necessity for
harmonization and standardization in
benchmarking surveillance procedures,
not available at present [56].
VAP AS QUALITY INDICATOR
Durocher [57] defines a quality indicator
as information that determines the degree
of adherence to a standard goal by de-
scribing a situation in a simple, validated,
reliable, and operational way with stan-
dard definitions that are reproducible,
both in time and between observers. Ac-
cording to Donabedian [58], quality of pa-
tient care can be stratified on different lev-
els: on the assessment of the structure of
a particular health care delivery system, on
the process of health care delivery, and on
defined outcomes of health care delivery.
All these levels can act as individual quality
indicators. Structural indicators consider
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Table 1. Ventilator-associated pneumonia (VAP): main risk factors and potential
quality indicators.
Topic VAP Evidence grade
Patient risk factors on hospital admission
Endogenous (intrinsic)
Immune suppressive therapy ++ All guidelines
Aspiration + All guidelines
Comorbidities ++ All guidelines
Acute respiratory distress syndrome ++ Level I
Malnutrition +++ All guidelines
Obesity + Canadian
Azotemia + CDC
Stomach acidity ++ CDC
Vaccination for pneumococci + 1A–B
Age 160 years + CDC
History of smoking and alcohol and drug abuse + All guidelines
Exogenous (extrinsic)
Important surgery ++ ATS
Trauma +++ ATS
Burns ++ ATS
Length of hospitalization ++ ATS
Protection of current antibiotic treatment ++ Level I–II
Sinusitis +++ Level II
Viral bronchitis/pneumonia + 1B
Quality indicators
Structure-related quality issues
Existence of a surveillance system +++ 1A, level I-II
Feedback of surveillance results +++ 1A
Education of staff +++ 1A
Nurse-to-patient ratio +++ Level II
HEPA filters on water supplies ++ 1B
Availability of bronchoscopy ++ Level I
Alcohol-based hand rub for hand hygiene +++ 1A
Infectious diseases experts ++ II
Infection-control policy +++ 1B-II, level II
Endotracheal suction systems ++ 1B
Heat and moisture exchangers ++ 1B, level II
Legionella policy +++ 1A–B, level II
Aspergillosis policy +++ 1A–B
Sedation policy ++ Level II
Weaning protocol ++ Level I
Process-related quality issues
Mechanical ventilation 12 days +++ 1A, level I
Noninvasive ventilation +++ II, level I
Oropharyngeal intubation route ++ 1B, level II
Short duration of ventilation +++ Level II
Reintubation rates ++ Level I
Positive end expiratory pressure + Level II
Frequent ventilator circuit changes ++ 1B, level I
Endotracheal tube cuff pressure ++ Level II
Supine head position ++ Level I
Intensiveness of diagnosis +++ Level II
Timing of tracheotomy + 1B
Subglottic secretion drainage +++ II, level II
(continued)
the environment, architecture, or the or-
ganization of the ICU—for example, the
nurse-to-patient ratio, the space between
beds, the availability of single rooms, or
education programs for physicians. Indi-
cators can also be process oriented—for
example, compliance with established
guidelines and recommended measures
for preventing, diagnosing, and treating
VAP; proportion of correctly isolated
methicillin-resistant Staphylococcus aureus
carriers; correct timing of elective intu-
bation; adequate sedation; and modalities
of ventilation. VAP-related outcome in-
dicators could assess tracheal and bron-
chial colonization with bacterial burden,
as well as the VAP or mortality rates (at-
tributable or not). The National Quality
Forum cites as outcome measures the
identification of trends and effectiveness
of mitigation strategies, operations, and
financial indicators of performance im-
provement, such as reduction in ICU bed
days, cost reductions to patients, payers,
and direct and indirect costs to hospitals
[44].
Table 1 summarizes main risk factors
and potential quality indicators on struc-
ture, process, and outcome levels related
to VAP, with the corresponding grade of
evidence in present guidelines. The list is
not exhaustive; it represents our opinion
about the possible impact or importance
of preventive actions. A priori, there is no
reason to assume that these indicators
would not reflect the quality needed to
prevent the outcome. Meaningful com-
parisons among different health care fa-
cilities should be possible. However, at the
present stage, the quantitative translation
of evidence levels into their role as quality
indicators remains an unresolved issue
that deserves further testing in clinical
trials.
Provided that a good data quality exists,
surveillance systems based on process in-
dicators are simpler to conduct than is
outcome-based surveillance, because er-
rors in procedure are more frequent than
VAP episodes and represent a good stim-
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Table 1. (Continued.)
Topic VAP Evidence grade
Removal of secretions ++ II
Transport out of the ICU ++ Level I
Number of devices ++ II
Postoperative spirometers +++ 1B
Mobilization of patients ++ 1A
Compliance with hand hygiene +++ 1A, level I
Compliance with gloving ++ 1A–B
Glycemic control ++ 1A
Early enteral feeding + 1B, level I
Transfusion of 14 units of blood ++ Level I
Vaccination for influenza ++ 1A
Oropharyngeal cleansing ++ II, level I
Selective digestive decontamination + Canadian, II
Stress ulcer prophylaxis No benefit? Level II
Outcome-related quality issues
Incidence of VAP +++ …
Attributable additional length of stay +++ …
Attributable mortality +++ …
Attributable costs +++ …
NOTE. Impact for preventive actions are indicated with plus signs: +, of concern, ++, important,
+++, very important. Three different guidelines were consulted for the ranking system for evidence
in the literature) Guidelines for Preventing Health-Care-Associated Pneumonia, 2003: Recommen-
dations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC) [36],
ranked according to the following categories: 1A, strongly recommended for implementation and
strongly supported by well-designed, experimental, clinical, or epidemiological studies; 1B, strongly
recommended for implementation and supported by some experimental, clinical, or epidemiological
studies and a strong theoretical rationale; 1C, required for implementation, as mandated by federal
and/or state regulation or standard; II, suggested for implementation and supported by suggestive
clinical or epidemiological studies or a theoretical rationale or a consensus by a panel of experts.
(2) American Thoracic Society (ATS) and Infectious Diseases Society of America Guidelines for the
Management of Adults with Hospital-Acquired, Ventilator-Associated, and Health Care–Associated
Pneumonia [60] are ranked according to the following levels: I (high), evidence comes from well-
conducted, randomized, controlled trials; II (moderate), evidence comes from well-designed, con-
trolled trials without randomization (including cohort, patient series, and case-control studies) and
also includes any large case series in which systematic analysis of disease patterns and/or microbial
etiology was conducted, as well as reports of new therapies that were not collected in a randomized
fashion; III (low), evidence comes from case studies and expert opinion. In some instances, therapy
recommendations come from antibiotic susceptibility data without clinical observations. (3) Canadian
Critical Care Society (Canadian) provides evidence-based clinical practice guideline for the prevention
of ventilator-associated pneumonia [35] but has no grading system. CDC, Centers for Disease Control
and Prevention; HEPA, high-efficiency particulate air; ICU, intensive care unit.
ulation for improvement in care [59].
Outcome variation emerges slowly and
takes time and a large sample size to be
detected. Most importantly, structure or
process indicators allow getting almost en-
tirely around the case mix and diagnosis
problems. For example, because nasopha-
ryngeal intubation is more likely than or-
opharyngeal intubation to lead to VAP, the
latter is recommended and could be com-
pared. Although the outcome—that is,
VAP rates—may differ according to case
mix and individual patient comorbidities
among centers, comparison of the pro-
cess—that is, compliance with orophar-
yngeal intubation—would be almost pa-
tient or center independent, more
cost-effective, and easier to observe. The
recorded sample size would be much
larger, because far more intubations could
be observed than could true occurrences
of VAP.
On the basis of risk factors identified
through epidemiological studies, interven-
tions have been tested in randomized trials
[60]. Improvement on a process level
could favorably change the outcome [61–
66]. To cite 1 concrete example, Mahul et
al. [67] randomly assigned intubated pa-
tients to VAP prevention by hourly subgl-
ottic secretion drainage or use of sucral-
fate. Subglottic secretion drainage
treatment was associated with a 2-fold
lower VAP incidence, whereas sucralfate
use was not. Clearly, the process modifi-
cation of subglottic secretion drainage fa-
vored the outcome. Theoretically, these in-
dicators can sometimes conflict with each
other—for example, attempts to shorten
intubation duration may lead to increased
rates of reintubation or to the intensive-
ness of diagnostic evaluation, thus leading
to increased transport out of the ICU.
National organizations use quality in-
dicators on the process and outcome lev-
els. To cite examples, VAP prevention by
the use of quality indicators was a com-
ponent of the Surgical Care Improvement
Project, the National Quality Forum [44],
and the Institute for Healthcare Improve-
ment 100,000 Lives Campaign [45]. The
latter 2 organizations used a so-called ven-
tilator bundle, which has 4 key compo-
nents and is based predominantly on pro-
cess indicators: elevation of the head of
the bed to 30–45, daily “sedation vaca-
tion,” peptic ulcer prophylaxis, and deep
venous thrombosis prophylaxis. Interest-
ingly, thrombosis prophylaxis is not a risk
factor for VAP, whereas ulcer prophylaxis
is itself a potential risk factor (table 1). In
this campaign, the bundle was an all-or-
nothing measurement and was not frag-
mented into individual components. Sim-
ilar interventions based on bundled
process indicators are gaining momentum
and have been successfully implemented
for VAP prevention [49, 68–70].
As yet, it is not known whether struc-
ture and process quality indicators are
more reliable or cost-effective than is the
measurement of outcome itself. Donabe-
dian [71] argued that the measurement of
neither process nor outcome is inherently
superior. Contrary to benchmarking of
VAP results, communication and public
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comparison of individual quality indica-
tors is easier and much less vulnerable for
misuse in the media than is uncontrolled,
erroneous information or ranking lists.
CONCLUSIONS
Benchmarking VAP rates as outcome pa-
rameters between institutions is hazardous
and potentially misleading. However, evi-
dence-based process indicators for the
prevention of VAP can serve as quality in-
dicators. Structure and outcome indica-
tors can be of additional use. Beyond the
detection of outbreaks and feedback of re-
sults, a well-defined surveillance system is
necessary to monitor, benchmark, and val-
idate all these efforts, with the overall ob-
jective being the reduction of the inci-
dence of VAP and the improvement of
patient safety and quality of care.
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